Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVID200 · 2 trials · 2 indications
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Incidence of treatment related adverse events
| Arm | Type | Description |
|---|---|---|
| Dose Level 1: 180 mg/m2 of AVID200 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation. |
| Dose Level 2: 550 mg/m2 of AVID200 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1 hour administered every three weeks. |
| Dose Level 3: 1100 mg/m2 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1.5 hours administered every three weeks. |
| Dose escalation | OTHER | Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc). Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period). |
| Name | Type | Description |
|---|---|---|
| AVID200 | DRUG | A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ |
Inclusion Criteria: * Patients with a documented (histologically or cytologically proven) solid tumor malignancy that is locally advanced or metastatic * Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability o...
AVID200 is an investigational small molecule being studied for the treatment of diffuse cutaneous systemic sclerosis (scleroderma) and malignant solid tumors. It is in Phase 1 clinical development and has not been approved by the FDA.
AVID200 is a transforming growth factor beta (TGFβ) inhibitor. It is designed to block TGFβ signaling, which is implicated in fibrosis and tumor growth. This mechanism is being evaluated in clinical trials for scleroderma and cancer.
AVID200 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and tolerability.
AVID200 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in scleroderma and one in malignant solid tumors.
AVID200 has been studied in two completed Phase 1 trials. NCT03831438 evaluated the drug in patients with diffuse cutaneous systemic sclerosis, and NCT03834662 assessed it in patients with malignant solid tumors. Both trials were conducted in the United States and Canada.
Yes, AVID200 is a transforming growth factor beta (TGFβ) inhibitor. It is being investigated for its potential to treat conditions associated with fibrosis and cancer by targeting the TGFβ pathway.